UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Can We Improve on the Rapid Assessment of Clinically Relevant Levels of Direct Acting Oral Anticoagulants (DOAC)?

Clinical and applied thrombosis/hemostasis, 2022-01, Vol.28, p.10760296221096422-10760296221096422

Walenga, Jeanine M.

2022

Volltextzugriff (PDF)

Heparin-induced thrombocytopenia: an update

Seminars in thrombosis and hemostasis, 2012-07, Vol.38 (5), p.483-496

2012

Volltextzugriff (PDF)

The DOAC (direct oral anticoagulant) Dipstick reliably excludes residual FXa inhibitors levels in the preoperative setting

Thrombosis research, 2024-07, Vol.239, p.109023-109023, Article 109023

2024

Volltextzugriff (PDF)

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination

Clinical and Applied Thrombosis/Hemostasis, 2021, Vol.27, p.10760296211021498

2021

Volltextzugriff (PDF)

Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancer

Critical reviews in oncology/hematology, 2013-10, Vol.88 (1), p.1-18

2013

Volltextzugriff (PDF)

Heparin: Much more than anti-IIa/anti-Xa

Journal de médecine vasculaire, 2020-05, Vol.45 (3), p.103-104

Walenga, Jeanine M.

2020

Volltextzugriff (PDF)

Angiopoietin-2 correlates with pulmonary embolism severity, right ventricular dysfunction, and intensive care unit admission

Vascular medicine (London, England), 2021-10, Vol.26 (5), p.556-560

2021

Volltextzugriff (PDF)

Zika and Chikungunya Virus and Risk for Venous Thromboembolism

Clinical and applied thrombosis/hemostasis, 2019-01, Vol.25, p.1076029618821184-1076029618821184

2019

Volltextzugriff (PDF)

The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update

Seminars in thrombosis and hemostasis, 2008-02, Vol.34 (1), p.86-96

2008

Volltextzugriff (PDF)

Enhanced Thrombin Formation in Patients With Ventricular Assist Devices Experiencing Bleeding: Insights From the Multicenter PREVENT Study

ASAIO journal (1992), 2023-03, Vol.69 (3), p.278-283

2023

Volltextzugriff (PDF)

Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia

Thrombosis journal, 2013-04, Vol.11 (1), p.7-7

2013

Volltextzugriff (PDF)

Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism

Clinical and applied thrombosis/hemostasis, 2022-06, Vol.28, p.10760296221104801-10760296221104801

2022

Volltextzugriff (PDF)

Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands

American Journal of Physiology: Cell Physiology, 2010-07, Vol.299 (1), p.C97-C110

2010

Volltextzugriff (PDF)

Protein C Pathway, Inflammation, and Pump Thrombosis in Patients With Left Ventricular Assist Devices

Clinical and applied thrombosis/hemostasis, 2020, Vol.26, p.1076029620959724-1076029620959724

2020

Volltextzugriff (PDF)

Sulodexide for the extended treatment of venous thromboembolism

International angiology, 2016-12, Vol.35 (6), p.531

2016

Volltextzugriff (PDF)

Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism

Clinical and applied thrombosis/hemostasis, 2023-01, Vol.29, p.10760296231165058-10760296231165058

2023

Volltextzugriff (PDF)

Harry L. Messmore, Jr., MD (1922–2011)

Seminars in thrombosis and hemostasis, 2012-11, Vol.38 (8), p.753-754

2012

Volltextzugriff (PDF)

Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin‐induced thrombocytopenia

British journal of haematology, 2008-10, Vol.143 (1), p.92-99

2008

Volltextzugriff (PDF)

Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device

Clinical and applied thrombosis/hemostasis, 2018-09, Vol.24 (6), p.965-972

2018

Volltextzugriff (PDF)

Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes

Clinical and applied thrombosis/hemostasis, 2018-12, Vol.24 (9_suppl), p.294S-300S

2018

Volltextzugriff (PDF)

Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devices

Biomarkers in medicine, 2016-10, Vol.10 (10), p.1095-1104

2016

Volltextzugriff (PDF)

Nonhemostatic adverse effects of anticoagulants and antiplatelet agents

Seminars in thrombosis and hemostasis, 2012-11, Vol.38 (8), p.884-892

2012

Volltextzugriff (PDF)

Low molecular weight heparins differ substantially: impact on developing biosimilar drugs

Seminars in thrombosis and hemostasis, 2011-04, Vol.37 (3), p.322-327

2011

Volltextzugriff (PDF)

Apixaban as an Alternate Oral Anticoagulant for the Management of Patients With Heparin-Induced Thrombocytopenia

Clinical and applied thrombosis/hemostasis, 2013-09, Vol.19 (5), p.482-487

2013

Volltextzugriff (PDF)

1 – 25 von 471

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(453)
Mit Volltextzugriff
(398)

Publikationsform

Sprache

Englisch
(466)
Deutsch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(232)
Science & Technology
(232)
Humans
(193)
Cardiovascular System & Cardiology
(172)
Hematology
(171)
Peripheral Vascular Disease
(156)
Biological And Medical Sciences
(97)
Medical Sciences
(90)
Male
(74)
Animals
(67)
Anticoagulants
(62)
Female
(62)
Pharmacology. Drug Treatments
(59)
Heparin - Adverse Effects
(56)
Thrombocytopenia - Chemically Induced
(56)
Heparin
(50)
Anticoagulants - Therapeutic Use
(41)
Blood. Blood Coagulation. Reticuloendothelial System
(40)
Heparin - Pharmacology
(35)
Adult
(33)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Can We Improve on the Rapid Assessment of Clinically Relevant Levels of Direct Acting Oral Anticoagulants (DOAC)?

Heparin-induced thrombocytopenia: an update

The DOAC (direct oral anticoagulant) Dipstick reliably excludes residual FXa inhibitors levels in the preoperative setting

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination

Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancer

Heparin: Much more than anti-IIa/anti-Xa

Angiopoietin-2 correlates with pulmonary embolism severity, right ventricular dysfunction, and intensive care unit admission

Zika and Chikungunya Virus and Risk for Venous Thromboembolism

The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update

Enhanced Thrombin Formation in Patients With Ventricular Assist Devices Experiencing Bleeding: Insights From the Multicenter PREVENT Study

Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia

Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism

Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands

Protein C Pathway, Inflammation, and Pump Thrombosis in Patients With Left Ventricular Assist Devices

Sulodexide for the extended treatment of venous thromboembolism

Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism

Prevention and management of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence

Harry L. Messmore, Jr., MD (1922–2011)

Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin‐induced thrombocytopenia

Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device

Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes

Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devices

Nonhemostatic adverse effects of anticoagulants and antiplatelet agents

Low molecular weight heparins differ substantially: impact on developing biosimilar drugs

Apixaban as an Alternate Oral Anticoagulant for the Management of Patients With Heparin-Induced Thrombocytopenia

Suchergebnisse filtern